JP2025535192A - マクロファージ活性の調整のための組成物及び方法 - Google Patents

マクロファージ活性の調整のための組成物及び方法

Info

Publication number
JP2025535192A
JP2025535192A JP2025542435A JP2025542435A JP2025535192A JP 2025535192 A JP2025535192 A JP 2025535192A JP 2025542435 A JP2025542435 A JP 2025542435A JP 2025542435 A JP2025542435 A JP 2025542435A JP 2025535192 A JP2025535192 A JP 2025535192A
Authority
JP
Japan
Prior art keywords
lilrb1
human
seq
lilrb2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025542435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025535192A5 (enExample
Inventor
カッセッタ，ルカ
マイアット，スティーブン
リース，キャロラ
ビー． ウィッチャー，クシシュトフ
Original Assignee
マコミクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マコミクス リミテッド filed Critical マコミクス リミテッド
Priority claimed from PCT/GB2023/050592 external-priority patent/WO2023170434A1/en
Publication of JP2025535192A publication Critical patent/JP2025535192A/ja
Publication of JP2025535192A5 publication Critical patent/JP2025535192A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2025542435A 2022-10-04 2023-03-13 マクロファージ活性の調整のための組成物及び方法 Pending JP2025535192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2214614.6A GB202214614D0 (en) 2022-10-04 2022-10-04 Compositions and methods for modulation of macrophage
GB2214614.6 2022-10-04
PCT/GB2023/050592 WO2023170434A1 (en) 2022-03-11 2023-03-13 Compositions and methods for modulation of macrophage activity

Publications (2)

Publication Number Publication Date
JP2025535192A true JP2025535192A (ja) 2025-10-22
JP2025535192A5 JP2025535192A5 (enExample) 2026-03-24

Family

ID=84000149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025542435A Pending JP2025535192A (ja) 2022-10-04 2023-03-13 マクロファージ活性の調整のための組成物及び方法

Country Status (8)

Country Link
JP (1) JP2025535192A (enExample)
KR (1) KR20250096720A (enExample)
CN (1) CN120435496A (enExample)
AU (1) AU2023232991A1 (enExample)
CR (1) CR20250172A (enExample)
GB (1) GB202214614D0 (enExample)
IL (1) IL319958A (enExample)
MX (1) MX2025003929A (enExample)

Also Published As

Publication number Publication date
MX2025003929A (es) 2025-05-02
CR20250172A (es) 2025-09-04
IL319958A (en) 2025-05-01
AU2023232991A1 (en) 2025-04-10
CN120435496A (zh) 2025-08-05
KR20250096720A (ko) 2025-06-27
GB202214614D0 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
US12209128B2 (en) Anti-PD-L1 antibodies
JP7345578B2 (ja) 新規抗ｐｄ－ｌ１抗体
US20230192847A1 (en) Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo
US11965026B2 (en) Anti-PD-L1 and IL-2 cytokines
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
CN110167964B (zh) 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN107530428B (zh) Icos的抗体
US20260049143A1 (en) Multispecific antibody with combination therapy for immuno-oncology
EP4458417A2 (en) Novel anti-pd-1 antibodies
US20160200815A1 (en) Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2017024515A1 (en) Novel anti-pd-1 antibodies
WO2020233539A1 (en) Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof
CA3198102A1 (en) Anti-dectin-1 antibodies and methods of use thereof
US20250197491A1 (en) Compositions and methods for modulation of macrophage activity
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
JP2025128164A (ja) 抗ｔｒｅｍ２抗体の使用方法
KR20250134230A (ko) 다중특이적 항체 및 이의 용도
CN114008077A (zh) 抗体和使用方法
WO2021207449A1 (en) Affinity matured anti-lap antibodies and uses thereof
JP2025535192A (ja) マクロファージ活性の調整のための組成物及び方法
KR20240026959A (ko) 항-ｔｒｅｍ-1 항체
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
TW202417485A (zh) 抗ｐｖｒｉｇ抗體及使用方法
CN116670169A (zh) 与pd-l1结合的多特异性结合化合物
HK40016537B (zh) 抗pd-1抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313